Brind.

NHS England Reverses NICE Decision, Clearing Enhertu for HER2-low Breast Cancer

2 reports, 1 independent Updated Sep 22
No new developments lately
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

England’s National Health Service has cleared Enhertu for use in patients with HER2-low metastatic breast cancer, reversing an earlier NICE recommendation that had rejected funding on cost-effectiveness grounds. The list price of Enhertu is £1,455 per 100 mg vial. The decision is expected to benefit around 1,000 women annually in England.

From insidermonkey.com

Why it matters

Some supportBrind's analysis of the reports

The clearance expands market access for Enhertu in one of Europe’s largest healthcare markets. This decision strengthens the product’s position in the indication and is noted as a key growth driver for AstraZeneca.

From insidermonkey.com

Who's involved

  • EnglandThe geographical region whose healthcare system implemented the drug clearance.
  • AstraZenecaThe company whose product, Enhertu, received the clearance.
  • Daiichi SankyoThe company partnered with AstraZeneca on the development and commercialization of Enhertu.
  • Department of Health and Social CareThe government agency responsible for implementing the drug into the national health service protocol.

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • AstraZenecaSpeculative

    AstraZeneca could see its revenue increase through wider patient uptake of Enhertu in the UK market.

  • Daiichi SankyoSpeculative

    Daiichi Sankyo could benefit from the increased sales of the joint Enhertu product.

How this reaches others

Each traced step by step, with the reporting behind it

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
1 more outlet ran the same wire story